N/A N=57 Mindfulness and CBT for Sleep
Hematologic Malignancy
Primary: Feasibility as Measured by Number of Participants Accrued to Single-arm Pilot — 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=27 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Childhood Acute Lymphoblastic Leukemia in Remission · Childhood Acute Myeloid Leukemia in Remission · Childhood Chronic Myelogenous Leukemia
Primary: Estimated Two-year Event-free Survival (EFS) — 66; 83 Percentage of patients
Phase 2 N=204 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Acute Myelogenous Leukemia · Lymphoid Leukemia · Chronic Myelogenous Leukemia
Primary: Median Disease-free Survival — 333 Days
N/A N=30 Exercise Prehab in Older Adults With Hematologic Malignancies
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants
N/A N=66 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Treatment-related Mortality Within the First 6 Months After Transplantation — 6 participants
Phase 2 N=11 Interleukin-1 Trap to Treat Autoinflammatory Diseases
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
N/A N=39 Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Phase 2 N=41 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
B-Cell Non-Hodgkin Lymphoma · Hematopoietic and Lymphoid Cell Neoplasm · Leukemia
Primary: Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant — 10; 2 Participants
Phase 2 N=136 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Immunosuppresion · Thrombocytopenia · Pancytopenia
Primary: Hematologic Response — 38; 20; 3 Participants
Phase 2 N=82 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Phase 3 N=87 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 65; 54 percentage of participants — p=.09
N/A N=14 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Phase 2 N=40 Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions
Infusion Reaction · Monoclonal Antibody
Primary: Number of Participants With Standard Infusion Reactions (SIR) at Cycle 1 and During Subsequent Cycles of Monoclonal Antibody Infusion — 14; 26; 4; 35 Participants
Phase 2 N=345 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Hematologic Neoplasms
Primary: Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 3 N=164 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99